{"commentary":{"count":51,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":33,"youtube":16,"podcast":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04266249\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT04266249","nct_id":"NCT04266249","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04266249. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"PRE-OPERATIVE/NEOADJUVANT THERAPY: Patients receive either paclitaxel or nab-paclitaxel IV on days 1, 8 and 15, or docetaxel IV on day 1 at the discretion of the treating oncologist. Patients also receive trastuzumab IV on day 1 or days 1, 8, and 15, and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.\n\nSURGERY: Within 42 days after last dose of neoadjuvant therapy, patients undergo standard of care lumpectomy and/or mastectomy.\n\nPOST-OPERATIVE.ADJUVANT THERAPY: Patients with pCR after surgery receive trastuzumab and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo standard of care radiation therapy and receive hormone therapy if appropriate.","label":"Arm A (pCR after surgery)","type":"EXPERIMENTAL"},{"description":"PRE-OPERATIVE/NEOADJUVANT THERAPY: Patients receive either paclitaxel or nab-paclitaxel IV on days 1, 8 and 15, or docetaxel IV on day 1 at the discretion of the treating oncologist. Patients also receive trastuzumab IV on day 1 or days 1, 8, and 15, and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.\n\nSURGERY: Within 42 days after last dose of neoadjuvant therapy, patients undergo standard of care lumpectomy and/or mastectomy.\n\nPOST-OPERATIVE/ADJUVANT THERAPY: Patients with remaining tumor after surgery receive standard of care trastuzumab emtansine for 14 doses in the absence of disease progression or unacceptable toxicity. Patients may also receive additional standard of care chemotherapy, as well as hormone therapy if appropriate.","label":"Arm B (residual invasive disease after surgery)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2038-12-31","type":"ESTIMATED"},"conditions":["Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Invasive Breast Carcinoma","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8"],"enrollment":{"count":2175,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Docetaxel","type":"DRUG"},{"name":"Lumpectomy","type":"PROCEDURE"},{"name":"Mastectomy","type":"PROCEDURE"},{"name":"Nab-paclitaxel","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"},{"name":"Pertuzumab","type":"BIOLOGICAL"},{"name":"Radiation Therapy","type":"RADIATION"},{"name":"Trastuzumab","type":"BIOLOGICAL"},{"name":"Trastuzumab Emtansine","type":"BIOLOGICAL"}],"last_update":"2026-09-14","lead_sponsor":"ECOG-ACRIN Cancer Research Group","official_title":"(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-10-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Recurrence-free survival (RFS)","timeFrame":"Up to 3 years after end of treatment"}],"references":[{"citation":"Tung N, Zhao F, DeMichele A, Prat A, Winer EP, Wright JL, Recht A, Weiss AC, Tjoe JA, Feldman SM, Rocque GB, Smith ML, O'Sullivan CC, Sardesai SD, Tang SC, Modi S, Irvin WJ, Unni N, Battelli C, Bagegni N, Krie AK, George MA, Telli ML, Borges VF, D'Abreo N, Shah P, Villagrasa P, Badve S, Partridge AH, Miller KD, Carey LA, Wolff AC. Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR. J Clin Oncol. 2026 Aug 20:JCO2502255. doi: 10.1200/JCO-25-02255. Online ahead of print.","pmid":"42623567","type":"DERIVED"}],"start_date":{"date":"2020-03-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","url":"https://clinicaltrials.gov/study/NCT04266249"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04266249"}